Literature DB >> 21679902

Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.

Claudio Rapezzi1, Candida C Quarta, Pier Luigi Guidalotti, Cinzia Pettinato, Stefano Fanti, Ornella Leone, Alessandra Ferlini, Simone Longhi, Massimiliano Lorenzini, Letizia Bacchi Reggiani, Christian Gagliardi, Pamela Gallo, Caterina Villani, Fabrizio Salvi.   

Abstract

OBJECTIVES: In a cohort of patients with hereditary transthyretin-related amyloidosis (ATTR), we aimed to assess the role of (99m)Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD) in detecting myocardial amyloid infiltration across a wide spectrum of cardiac involvement and in predicting major adverse cardiac events (MACE).
BACKGROUND: Hereditary transthyretin-related amyloidosis is a challenging and underdiagnosed condition where both early diagnosis and prognosis remain problematic.
METHODS: We evaluated 63 patients with ATTR: 40 with and 23 without echocardiographically diagnosed amyloidotic cardiomyopathy (AC). Myocardial uptake of (99m)Tc-DPD scintigraphy was semiquantitatively and visually assessed at 5 min and 3 h.
RESULTS: All patients with AC showed moderate-to-severe myocardial tracer uptake (i.e., visual score ≥2). Within the subgroup without AC, only 4 patients (with Ala36Pro, Gly47Ala, Thr49Ala, and Glu89Gln transthyretin mutations) showed myocardial tracer uptake and abnormal heart/whole body retention (H/WB) values: in all these cases endomyocardial biopsies showed amyloidotic infiltration. The H/WB was positively correlated with left ventricular (LV) mean wall thickness (Pearson's r=0.695, p<0.001) and negatively with LV ejection fraction (r=-0.368, p=0.004). The H/WB was an unfavorable predictor of MACE-free survival at Cox univariate analysis and contributed to the multivariate model. Notably, LV wall thickness >12 mm in combination with H/WB >7.5 was associated with the highest event rate.
CONCLUSIONS: In ATTR, (99m)Tc-DPD scintigraphy can identify myocardial infiltration across a wide spectrum of morphologic/functional cardiac involvement, allowing an early diagnosis of the disease (even before the appearance of echocardiographic abnormalities). The (99m)Tc-DPD myocardial uptake is a prognostic determinant of "cardiac" outcome in ATTR, either alone or in combination with LV wall thickness.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21679902     DOI: 10.1016/j.jcmg.2011.03.016

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  88 in total

1.  Imaging Findings and Literature Review of (18)F-FDG PET/CT in Primary Systemic AL Amyloidosis.

Authors:  Joo Hee Lee; Ga Yeon Lee; Seok Jin Kim; Ki Hyun Kim; Eun-Seok Jeon; Kyung-Han Lee; Byung-Tae Kim; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2015-05-13

2.  Pattern of myocardial 99mTc-HMDP uptake and impact on myocardial function in patients with transthyretin cardiac amyloidosis.

Authors:  Sarah Pradel; Stéphanie Brun; Gérard Victor; Pierre Pascal; Pauline Fournier; David Ribes; Yoan Lavie-Badie; Michel Galinier; Didier Carrié; Isabelle Berry; Olivier Lairez
Journal:  J Nucl Cardiol       Date:  2018-06-07       Impact factor: 5.952

Review 3.  Role of Imaging in Evaluating Infiltrative Heart Disease.

Authors:  Sanjay Divakaran; Avinainder Singh; Bradley Collins; Tomas Vita; Rodney H Falk; Marcelo F Di Carli; Ron Blankstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-01

4.  (99m)Tc-HMDP scintigraphy rectifies wrong diagnosis of AL amyloidosis.

Authors:  Arnault Galat; Axel Van Der Gucht; Magali Colombat; David Attias; Emmanuel Itti; Michel Meignan; Fabien Lebras; Valérie Molinier-Frenkel; Nicole Benhaiem; Aziz Guellich; Jean Rosso; Thibaud Damy
Journal:  J Nucl Cardiol       Date:  2015-05-22       Impact factor: 5.952

Review 5.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

6.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

7.  Technetium 99m pyrophosphate radioisotope for diagnosis and prognosis of transthyretin cardiac amyloidosis: A call for collaboration.

Authors:  Adam Castaño; Mathew S Maurer; Sabahat Bokhari
Journal:  J Nucl Cardiol       Date:  2017-02-01       Impact factor: 5.952

8.  The evolving landscape of nuclear imaging in cardiac amyloidosis.

Authors:  Steven J Promislow; Terrence D Ruddy
Journal:  J Nucl Cardiol       Date:  2018-05-18       Impact factor: 5.952

9.  Cardiac amyloidosis: A new challenge of multimodality imaging.

Authors:  Carmela Nappi; Roberta Assante; Emilia Zampella; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2018-06-26       Impact factor: 5.952

Review 10.  Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.

Authors:  David L Narotsky; Adam Castano; Jonathan W Weinsaft; Sabahat Bokhari; Mathew S Maurer
Journal:  Can J Cardiol       Date:  2016-05-13       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.